Positive Association Between Serum Insulin-Like Growth Factor-1 and Cognition in Patients with Cerebral Small Vessel Disease

J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105790. doi: 10.1016/j.jstrokecerebrovasdis.2021.105790. Epub 2021 Apr 18.

Abstract

Cognitive impairment is one of the main complications of cerebral small vessel disease (CSVD). Serum insulin-like growth factor-1 (IGF-1) might serve as a marker for the risk of cognitive decline in patients with CSVD. We investigated the association of IGF-1 with the development of cognitive impairment in patients with CSVD. We included 216 patients with CVSD (mean age, 67.57 ± 8.53 years; 31.9% female). We compared 117 (54.2%) patients who developed cognitive impairment with 99 (45.8%) patients without cognitive impairment. Patients who developed cognitive impairment had significantly lower levels of IGF-I (p < 0 .001), suggesting that altered IGF-1 signaling may be a risk factor for cognitive decline in patients with CSVD.

Keywords: Cerebral small vessel disease; Cognitive impairment; IGF-1; Insulin resistance; Type 2 diabetic.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Cerebral Small Vessel Diseases / blood
  • Cerebral Small Vessel Diseases / complications*
  • Cerebral Small Vessel Diseases / diagnosis
  • Cognition*
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / etiology*
  • Cognitive Dysfunction / psychology
  • Down-Regulation
  • Female
  • Humans
  • Insulin-Like Growth Factor I / analysis*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors

Substances

  • Biomarkers
  • IGF1 protein, human
  • Insulin-Like Growth Factor I